Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real‐world data
M Rimini, L Fornaro, S Lonardi, M Niger… - Liver …, 2023 - Wiley Online Library
Abstract Background The TOPAZ‐1 phase III trial reported a survival benefit with the anti‐
programmed death cell ligand 1 (anti‐PD‐L1) durvalumab in combination with gemcitabine …
programmed death cell ligand 1 (anti‐PD‐L1) durvalumab in combination with gemcitabine …
[HTML][HTML] The roles of epigenetic regulation in cholangiocarcinogenesis
B Zhong, Q Liao, X Wang, X Wang, J Zhang - Biomedicine & …, 2023 - Elsevier
Cholangiocarcinoma (CCA), a heterogeneous malignancy of bile duct epithelial cells, is
characterized by aggressiveness, difficult diagnosis, and poor prognosis due to limited …
characterized by aggressiveness, difficult diagnosis, and poor prognosis due to limited …
Ivosidenib: A Review in Advanced Cholangiocarcinoma
JE Frampton - Targeted Oncology, 2023 - Springer
Ivosidenib (Tibsovo®), a first-in-class, oral small molecule, potent and selective inhibitor of
mutant isocitrate dehydrogenase 1 (mIDH1), is approved in the EU and USA for the …
mutant isocitrate dehydrogenase 1 (mIDH1), is approved in the EU and USA for the …
[HTML][HTML] Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters
M Rimini, E Loi, C Fabregat-Franco, V Burgio… - European Journal of …, 2022 - Elsevier
Background IDH1-mutated intrahepatic cholangiocarcinomas (IDH1m iCCAs) could be
treated with anti-IDH1 drugs, although the high heterogeneity in this class of tumours could …
treated with anti-IDH1 drugs, although the high heterogeneity in this class of tumours could …
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience
M Rimini, V Burgio, L Antonuzzo… - Therapeutic …, 2023 - journals.sagepub.com
Background: The results of the phase III ClarIDHy trial led to the FDA approval of ivosidenib
as a therapeutic option for patients with locally advanced or metastatic cholangiocarcinoma …
as a therapeutic option for patients with locally advanced or metastatic cholangiocarcinoma …
[HTML][HTML] Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population
M Rimini, L Fornaro, MD Rizzato, L Antonuzzo… - European Journal of …, 2024 - Elsevier
Abstract Background The TOPAZ-1 phase III trial showed a survival benefit with durvalumab
plus gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). To …
plus gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). To …
Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma
M Rimini, C Fabregat-Franco, V Burgio, S Lonardi… - Scientific Reports, 2022 - nature.com
Abstract IDH1-mutated cholangiocarcinomas (CCAs) are an interesting group of neoplasia
with particular behavior and therapeutic implications. The aim of the present work is to …
with particular behavior and therapeutic implications. The aim of the present work is to …
Prognostic model for oversurvival and tumor-specific survival prediction in patients with advanced extrahepatic cholangiocarcinoma: a population-based analysis
Y Zhang, C Qiao, P Zhao, C Zhang - BMC gastroenterology, 2023 - Springer
Background The prognosis of patients with extrahepatic cholangiocarcinoma (ECCA) must
be determined with precision. However, the usual TNM staging system has the drawback of …
be determined with precision. However, the usual TNM staging system has the drawback of …
Real-world data on ivosidenib in patients with previously treated isocitrate dehydrogenase 1-mutated intrahepatic cholangiocarcinomas: an early exploratory analysis
M Rimini, V Burgio, L Antonuzzo, L Rimassa… - Targeted Oncology, 2022 - Springer
Background The results of the phase III ClarIDHy trial have led to US FDA approval of
ivosidenib as a therapeutic option for patients with locally advanced or metastatic …
ivosidenib as a therapeutic option for patients with locally advanced or metastatic …
Different genomic clusters impact on responses in advanced biliary tract cancer treated with cisplatin plus gemcitabine plus durvalumab
Background The results reported in the TOPAZ-1 phase III trial led to the approval of the
combination of cisplatin and gemcitabine with durvalumab as the new first-line standard of …
combination of cisplatin and gemcitabine with durvalumab as the new first-line standard of …